Protalix reports FY2025 results; EC approves Elfabrio E4W regimen triggering $25M milestone

Protalix BioTherapeutics, Inc.

EC approved Elfabrio 2mg/kg every-4-weeks dosing for stable adults with Fabry in EU; $25M milestone from Chiesi triggered.
Total 2026 revenue guided to $78M-$83M including milestone; Elfabrio sales $33-35M, Elelyso $20-23M.
Phase 2 RELEASE trial for PRX-115 (uncontrolled gout) actively enrolling; top-line data expected H2 2027.
Company expects cash balance ~$50M by April 2026 with no outstanding debt or warrants.
No specific FY2025 financial numbers disclosed in the press release; focus on business and regulatory milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.

Period: the fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 18, 2026, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025 and provided a business and clinical update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-029846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.